The Roche group has nudged its sales forecast higher for 2019 following a strong performance of its multiple sclerosis, haemophilia and cancer drugs and four regulatory approvals in the first nine months of the year. The Switzerland-based company said it expects to raise its dividend again this year after paying CHF 8.70 per share in 2018.
